Lupin planning to approach USFDA for re-inspection of key plants

15 Jun 2020 Evaluate

Lupin is planning to approach the US health regulator for re-inspection of its manufacturing plants in Goa, Pithampur (Madhya Pradesh) and Somerset (US) in the next few months. The company's Unit 2 manufacturing plant in Pithampur, along with its Goa site, is under the US Food and Drug Administration's (USFDA) warning letter since November 2017 for violation of current goods manufacturing practices. The US drug regulator, after inspecting the two sites, had expressed concerns over quality-control procedures that include handling of out-of-specification results and conducting hold-time studies.

On the other hand, the Somerset (New Jersey) plant is currently under the official action indicated (OAI) status, which means the USFDA may withhold approvals of pending applications or supplements from the facility.

Lupin is an innovation led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2138.65 -12.40 (-0.58%)
01-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.20
Dr. Reddys Lab 1182.75
Cipla 1325.85
Zydus Lifesciences 878.80
Lupin 2138.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×